Some drugs,banned in other countries,allowed in India: Govt

Image
Press Trust of India New Delhi
Last Updated : Nov 25 2016 | 4:57 PM IST
Some drugs, which are banned in other countries, have been allowed to be sold in India subject to certain provisions, the Lok Sabha was informed today.
Minister of State for Health Faggan Singh Kulaste in a written reply said that the drugs which have been allowed are nimesulide, analgin and pioglitazone.
"Safety and efficacy issues relating to certain drugs which have been banned in some countries have been examined and some of these have been allowed for continued marketing subject to stipulated conditions or restrictions.
"They include Nimesulide - the manufacture, sale and distribution of nimesulide formation for human use in children below 12 years of age has been prohibited in the country.
"Analgin - The manufacture for sale, sale and distribution of analgin and its formulations containing analgin for human use was initially suspended into the country w.E.F June 18, 2013. Subsequently, the ban was revoked subject to the condition that manufacturers will be required to mention the following on their package insert and promotional literature of the drug," the Minister said.
Elaborating about the literature, the Minister said that "The drug is indicated for severe pain and pain due to tumour and also for brining down temperature in refractory cases when other antipyretics fail to do so" should be mentioned.
In case of Pioglitazone, the manufacture for sale, sale and distribution of the drug and formulations containing pioglitazone for human use was initially suspended w.E.F 18.6 2013.
Subsequently the suspension was revoked subject to condition that the manufacture shall mention "the drug should not be used as first line of therapy for diabetes" and the manufacturer should clearly mention in bold red in a warning box "Advice for healthcare professionals - patients with active bladder cancer or with a history of bladder cancer and those with investigated haematuria should not receive pioglitazone" among others.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Nov 25 2016 | 4:57 PM IST

Next Story